Jason R. Westin
Led the ZUMA-7 overall survival analysis that made CAR-T the standard second-line therapy for early-relapsing lymphoma.
Overview
Jason Westin was first author of the ZUMA-7 overall survival report, which showed axicabtagene ciloleucel improves survival compared with standard chemoimmunotherapy and transplant in primary refractory or early relapsed large B-cell lymphoma, the first randomised survival benefit for a CAR-T therapy and the trial that moved CAR-T into second line. He leads the Smart Start precision-medicine trials in DLBCL and lymphoma clinical research at MD Anderson.
Pages like this
not linked directly; found by shared links- PersonSattva S. Neelapu
Shares ZUMA-7, Axicabtagene ciloleucel, MD Anderson Cancer Center, CD19 and the tags lymphoma, car-t.
- PersonFrederick L. Locke
Shares ZUMA-7, Axicabtagene ciloleucel, ZUMA-7: axi-cel CAR-T instead of salvage chemotherapy and transplant for large B-cell lymphoma that relapses early, CD19.
- PersonStephen J. Schuster
Shares CD19, Diffuse large B-cell lymphoma, CAR-T cell therapy and the tags lymphoma, car-t.
- PersonMichael L. Wang
Shares MD Anderson Cancer Center, CD19, CAR-T cell therapy and the tags lymphoma, car-t.
- PairingEarly relapse: CAR-T before transplant
Shares ZUMA-7, ZUMA-7: axi-cel CAR-T instead of salvage chemotherapy and transplant for large B-cell lymphoma that relapses early, Diffuse large B-cell lymphoma, CAR-T cell therapy.
- Key paperZUMA-1: axicabtagene ciloleucel for refractory large B-cell lymphoma, the first CAR-T approved for lymphoma
Shares ZUMA-7, Axicabtagene ciloleucel, ZUMA-7: axi-cel CAR-T instead of salvage chemotherapy and transplant for large B-cell lymphoma that relapses early, MD Anderson Cancer Center.
- TrialTRANSFORM
Shares ZUMA-7: axi-cel CAR-T instead of salvage chemotherapy and transplant for large B-cell lymphoma that relapses early, CD19, Diffuse large B-cell lymphoma, CAR-T cell therapy.
- PersonMichel Sadelain
Shares CD19, Diffuse large B-cell lymphoma, CAR-T cell therapy and the tag car-t.